President of NOVARTIS

Holds a degree in Medicine from the Universidad Autónoma de Madrid and has received management training from IESE Business School. With more than twenty years of experience in the pharmaceutical industry, she has developed an international career in strategic areas such as market access, health economics, therapeutic value and biomedical innovation.  

Prior to her appointment at Novartiss, she worked at Gilead Sciences —most recently as Global Value & Access Head for HIV based in London— and previously held management positions in Switzerland and Austria. During her career, she has led key therapeutic areas such as HIV, haematology and oncology in different European markets.   

Previously, she spent a long period at Sanofi, where she was Market Access Director in Spain, Europe & Canada Market Access Senior Manager in Paris and Head of Health Economics in Madrid, leading access, economic evaluation and strategic planning projects in multiple markets.  

Her experience also includes more than four years at Schering AG, where she was R&D Clinical Advisor and later Head of Health Economics, participating in clinical development and the definition of value and evidence strategies in different therapeutic areas. 

In April 2025, she took over as president of Novartis Spain, becoming the first woman to head the subsidiary. From her position, she promotes innovation strategy, access to innovation, collaboration with the healthcare system, and the development of transformative therapies aimed at improving patients’ lives.